PubRank

Per Svenningsson

Author PubWeight™ 102.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A 2004 3.87
2 Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet 2013 2.62
3 How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007 2.29
4 Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics 2013 2.11
5 Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2010 2.09
6 Adenosine and brain function. Int Rev Neurobiol 2005 1.97
7 Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 2002 1.91
8 Phactrs 1-4: A family of protein phosphatase 1 and actin regulatory proteins. Proc Natl Acad Sci U S A 2004 1.86
9 S100A10 regulates plasminogen-dependent macrophage invasion. Blood 2010 1.85
10 Depression in Parkinson disease--epidemiology, mechanisms and management. Nat Rev Neurol 2011 1.69
11 Peptidomics-based discovery of novel neuropeptides. J Proteome Res 2003 1.65
12 Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 2008 1.63
13 Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci 2009 1.62
14 The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. Neuron 2005 1.57
15 Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry 2014 1.54
16 Heat stabilization of the tissue proteome: a new technology for improved proteomics. J Proteome Res 2009 1.29
17 The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res 2008 1.28
18 The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 2004 1.27
19 Phosphorylation of DARPP-32 at Threonine-34 is required for cocaine action. Neuropsychopharmacology 2006 1.24
20 EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2014 1.23
21 Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. Biol Psychiatry 2010 1.19
22 Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. J Proteome Res 2006 1.17
23 Molecular profiling of experimental Parkinson's disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry. J Proteome Res 2004 1.17
24 Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci U S A 2004 1.16
25 Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc Natl Acad Sci U S A 2013 1.09
26 Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. Neuropharmacology 2008 1.08
27 Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 2005 1.07
28 p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci 2013 1.07
29 The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: stathmin 2-20 and peptides as sample quality indicators. Proteomics 2007 1.07
30 Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci U S A 2008 1.06
31 Pharmacology of adenosine A2A receptors and therapeutic applications. Curr Top Med Chem 2003 1.04
32 Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol 2011 1.03
33 Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology 2003 1.00
34 Physiological role for casein kinase 1 in glutamatergic synaptic transmission. J Neurosci 2005 1.00
35 5-HT7 receptor stimulation by 8-OH-DPAT counteracts the impairing effect of 5-HT(1A) receptor stimulation on contextual learning in mice. Eur J Pharmacol 2008 0.99
36 Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. Neuroimage 2011 0.99
37 A role for p11 in the antidepressant action of brain-derived neurotrophic factor. Biol Psychiatry 2010 0.99
38 Regulation of fibrinolysis by S100A10 in vivo. Blood 2011 0.98
39 Co-expression of serotonin 5-HT(1B) and 5-HT(4) receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum. Neuropharmacology 2011 0.97
40 Antipsychotic drugs regulate hedgehog signaling by modulation of 7-dehydrocholesterol reductase levels. Mol Pharmacol 2010 0.94
41 S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther 2007 0.94
42 Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci Lett 2013 0.92
43 Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol 2009 0.91
44 Neuropeptidomics: MS applied to the discovery of novel peptides from the brain. Anal Chem 2007 0.90
45 Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci 2011 0.89
46 Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiol Behav 2007 0.89
47 Mass spectrometry imaging, an emerging technology in neuropsychopharmacology. Neuropsychopharmacology 2013 0.87
48 Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease. Mol Cell Proteomics 2009 0.87
49 Deuterated matrix-assisted laser desorption ionization matrix uncovers masked mass spectrometry imaging signals of small molecules. Anal Chem 2012 0.87
50 De novo mutations in ataxin-2 gene and ALS risk. PLoS One 2013 0.86
51 (11)C-CUMI-101, a PET radioligand, behaves as a serotonin 1A receptor antagonist and also binds to α(1) adrenoceptors in brain. J Nucl Med 2014 0.86
52 MRI diffusion in Parkinson's disease: using the technique's inherent directional information to study the olfactory bulb and substantia nigra. J Parkinsons Dis 2012 0.86
53 An automated method for scanning LC-MS data sets for significant peptides and proteins, including quantitative profiling and interactive confirmation. J Proteome Res 2007 0.86
54 Protection of stress-induced impairment of hippocampal/prefrontal LTP through blockade of glucocorticoid receptors: implication of MEK signaling. Exp Neurol 2008 0.85
55 Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain. Neuropharmacology 2006 0.85
56 DARPP-32 involvement in the photic pathway of the circadian system. J Neurosci 2006 0.84
57 Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. J Neurochem 2003 0.84
58 Increased levels of ubiquitin in the 6-OHDA-lesioned striatum of rats. J Proteome Res 2005 0.84
59 Pyrylium Salts as Reactive Matrices for MALDI-MS Imaging of Biologically Active Primary Amines. J Am Soc Mass Spectrom 2015 0.84
60 Cholesterol depletion reduces serotonin binding and signaling via human 5-HT(7(a)) receptors. Eur J Pharmacol 2006 0.83
61 Coupling surface plasmon resonance to mass spectrometry to discover novel protein-protein interactions. Nat Protoc 2009 0.83
62 S100B overexpressing mutant mice exhibit prolonged behavioural and biochemical responses towards repeated intermittent binge treatments with MDMA. Int J Neuropsychopharmacol 2008 0.82
63 A noncanonical postsynaptic transport route for a GPCR belonging to the serotonin receptor family. J Neurosci 2012 0.82
64 Behavioral and biochemical responses to d-amphetamine in MCH1 receptor knockout mice. Synapse 2008 0.82
65 Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients. J Clin Invest 2015 0.82
66 7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier. J Lipid Res 2013 0.82
67 Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Res 2006 0.81
68 Regulation of serotonin receptor function in the nervous system by lipid rafts and adaptor proteins. Exp Cell Res 2010 0.81
69 Use of surface plasmon resonance coupled with mass spectrometry reveals an interaction between the voltage-gated sodium channel type X alpha-subunit and caveolin-1. J Proteome Res 2008 0.81
70 Functional GPR37 trafficking protects against toxicity induced by 6-OHDA, MPP+ or rotenone in a catecholaminergic cell line. J Neurochem 2012 0.81
71 Modulation of monoamine receptors by adaptor proteins and lipid rafts: role in some effects of centrally acting drugs and therapeutic agents. Annu Rev Pharmacol Toxicol 2011 0.81
72 Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission. Neuropharmacology 2008 0.81
73 Increased striatal mRNA and protein levels of the immunophilin FKBP-12 in experimental Parkinson's disease and identification of FKBP-12-binding proteins. J Proteome Res 2007 0.81
74 Cellular localization and function of DARPP-32 in the rodent retina. Eur J Neurosci 2007 0.80
75 Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo. J Med Chem 2012 0.80
76 Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression. Neurochem Int 2011 0.80
77 Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain. Neurotoxicology 2007 0.80
78 5-HT1A and 5-HT7 receptor crosstalk in the regulation of emotional memory: implications for effects of selective serotonin reuptake inhibitors. Neuropharmacology 2012 0.80
79 Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects. Neuropharmacology 2011 0.80
80 GPR37 protein trafficking to the plasma membrane regulated by prosaposin and GM1 gangliosides promotes cell viability. J Biol Chem 2013 0.80
81 Caveolin-1 affects serotonin binding and cell surface levels of human 5-HT7(a) receptors. FEBS Lett 2007 0.79
82 Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology (Berl) 2011 0.79
83 Tianeptine potentiates AMPA receptors by activating CaMKII and PKA via the p38, p42/44 MAPK and JNK pathways. Neurochem Int 2011 0.79
84 Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3. Arch Immunol Ther Exp (Warsz) 2014 0.78
85 Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease. Neuropharmacology 2008 0.78
86 A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease. JIMD Rep 2011 0.78
87 Distribution, level, pharmacology, regulation, and signaling of 5-HT6 receptors in rats and marmosets with special reference to an experimental model of parkinsonism. J Comp Neurol 2011 0.77
88 Cholesterol reduction attenuates 5-HT1A receptor-mediated signaling in human primary neuronal cultures. Naunyn Schmiedebergs Arch Pharmacol 2008 0.77
89 Reduced phosphorylation of GluA1 subunits relates to anxiety-like behaviours in mice. Int J Neuropsychopharmacol 2013 0.77
90 Controlled-pH tissue cleanup protocol for signal enhancement of small molecule drugs analyzed by MALDI-MS imaging. Anal Chem 2012 0.77
91 Diffusion tensor fiber tractography of the olfactory tract. Magn Reson Imaging 2010 0.76
92 No correlation between serotonin and its metabolite 5-HIAA in the cerebrospinal fluid and [(11) C]AZ10419369 binding measured with PET in healthy volunteers. Synapse 2014 0.75
93 Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice. J Neurochem 2012 0.75
94 Genotype-phenotype analysis in inherited prion disease with eight octapeptide repeat insertional mutation. Prion 2013 0.75
95 Identification of protein-protein interactions by surface plasmon resonance followed by mass spectrometry. Curr Protoc Protein Sci 2011 0.75
96 Using biomarkers to disentangle different causes of Parkinsonism. J Neurol Neurosurg Psychiatry 2012 0.75
97 The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid. Biomark Med 2014 0.75
98 Studies of depression-related states in animal models of Parkinsonism. J Parkinsons Dis 2012 0.75
99 Patients are doing it for themselves: A survey on disease-specific knowledge acquisition among people with Parkinson's disease in Sweden. Health Informatics J 2017 0.75
100 Patient-driven N-of-1 in Parkinson's Disease. Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia. Methods Inf Med 2017 0.75